Efficacy and safety of the ß3-adrenoceptor agonist mirabegron in the treatment of OAB patients for whom comorbid neurologic disorders cannot be ruled out as etiology for bladder symptoms: a post-hoc analysis of pooled data from 3 randomised Phase III trials

Van Kerrebroeck P1, Chartier-Kastler E2, Cruz F3, Barkin J4, Blauwet M B5, Martin N5, Siddiqui E6

Abstract Category

Neurourology: Clinical

Abstract 402
Non Discussion Poster
Scientific Non Discussion Poster Session 34
Clinical Trial Incontinence Overactive Bladder
1. Maastricht University Medical Center, Maastricht, Netherlands, 2. Pitie-Salpetrière Academic Hospital, Paris, France, 3. Hospital S. João and Faculty of Medicine of Porto, Porto, Portugal, 4. University of Toronto, Toronto, Canada, 5. Astellas Pharma Global Development, Northbrook, IL, USA, 6. Astellas Pharma Europe Ltd, Chertsey, Surrey, UK and Department of Urology, Ealing Hospital, London, UK